累计对外授权近300亿后,上海“创新药黑马”拟易主,中生制药超35亿收购礼新医药

时代周报
16 Jul

图片来源:图虫创意中国生物制药(01177.HK,下称“中生制药”)“买买买”加速,拟掷逾5亿美元将创新药黑马礼新医药收入囊中。7月15日晚间,中生制药对外宣布,其将以约5亿美元(约合人民币35.91亿元)的净代价收购礼新医药95.09%股权。加上此前持有的4.91%股权,此次交易完成后,礼新医药将成为中生制药间接全资附属公司。届时,礼新医药主要研发和管理团队,以及其双抗、ADC(抗体偶联药物)等...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10